Stonegate Capital Partners has updated its coverage on Viemed Healthcare, Inc., revealing the company's substantial financial performance in fiscal year 2025. Viemed reported net revenue growth of 21% year-over-year to $270.3 million, generating $14.9 million in net income and delivering record adjusted EBITDA of $61.4 million. This growth was supported by continued platform momentum and contributions from the Lehan's acquisition, alongside broader industry shifts toward in-home care and accelerating adoption of sleep and resupply services.
The company faced a key headwind from the updated National Coverage Determination, which introduced additional documentation requirements and tightened coverage criteria, temporarily moderating ventilator patient growth. However, Stonegate noted that this regulatory change did not affect reimbursement levels, and ventilator activity has already begun to normalize. Viemed ended the fiscal year with free cash flow up 141% year-over-year, indicating strong financial health.
Stonegate's analysis highlights several important strategic developments for Viemed. Sleep and resupply services are now overtaking ventilation in importance, which improves the quality of recurring revenue and reduces regulatory sensitivity. The acquisition of Lehan's broadens Viemed's commercial exposure, diversifies its payor base, and creates a longer runway for scaled growth. These factors contribute to a more resilient business model in the evolving healthcare landscape.
Despite some margin mix pressure, Stonegate's assessment of Viemed's FY26 guidance and current valuation suggests that the company's durable growth prospects remain underappreciated by the market. The firm's analysis indicates that Viemed is well-positioned to capitalize on the ongoing shift toward home-based healthcare services, which has been accelerating across the industry. For more detailed information, readers can access the full announcement through Stonegate Capital Partners' website.
The broader implications of Viemed's performance extend beyond the company itself, reflecting important trends in healthcare delivery. The transition to in-home care represents a fundamental shift in how medical services are provided, potentially reducing healthcare costs while improving patient outcomes and satisfaction. Viemed's success in navigating regulatory challenges while expanding its service offerings demonstrates how healthcare companies can adapt to changing market conditions and regulatory environments.
For investors and industry observers, Viemed's financial results and strategic positioning offer insights into the viability of home-based healthcare models. The company's ability to maintain growth despite regulatory headwinds suggests resilience in its business approach, while its expansion into sleep and resupply services indicates successful diversification beyond its core ventilator business. These developments have significance for healthcare providers, payors, and patients who are increasingly seeking alternatives to traditional hospital-based care.
